Long Cheng-Yu, Hsu Chun-Shuo, Jang Mei-Yu, Liu Cheng-Min, Chiang Po-Hui, Tsai Eing-Mei
Graduate Institute of Medicine, Center of Excellence for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Int Urogynecol J. 2011 Feb;22(2):233-9. doi: 10.1007/s00192-010-1262-6. Epub 2010 Sep 10.
This study aims to compare clinical outcome using the Perigee/Apogee® vs. Prolift® devices for the treatment of pelvic organ prolapse (POP).
One hundred and eight women with POP stages II to IV were scheduled for either Perigee/Apogee® (Perigee group; n = 60) or Prolift® device (Prolift group; n = 48). Preoperative and postoperative assessments included pelvic examination, urodynamic study, and a personal interview about urinary and sexual symptoms.
Despite different follow-up period (20 months for the Perigee group vs. 12 months for Prolift group; P < 0.01), the success rates for two groups were comparable (P > 0.05). Postoperative points Aa and Ba of Prolift group were significantly higher than the other group (P < 0.01). The prevalences of detrusor overactivity and urinary symptoms decreased significantly postoperatively in both groups (P < 0.05). Comparisons of all operative complications revealed no significant differences between the two groups (P > 0.05).
Perigee/Apogee® and Prolift® devices for POP repair have comparable success rates, mesh-related morbidities, and similar impacts on functional outcome.
本研究旨在比较使用Perigee/Apogee®与Prolift®装置治疗盆腔器官脱垂(POP)的临床效果。
108例II至IV期盆腔器官脱垂女性患者被安排接受Perigee/Apogee®治疗(Perigee组;n = 60)或Prolift®装置治疗(Prolift组;n = 48)。术前和术后评估包括盆腔检查、尿动力学研究以及关于泌尿和性症状的个人访谈。
尽管随访期不同(Perigee组为20个月,Prolift组为12个月;P < 0.01),但两组的成功率相当(P > 0.05)。Prolift组术后的Aa点和Ba点显著高于另一组(P < 0.01)。两组术后逼尿肌过度活动和泌尿症状的发生率均显著降低(P < 0.05)。两组所有手术并发症的比较均无显著差异(P > 0.05)。
用于盆腔器官脱垂修复的Perigee/Apogee®和Prolift®装置成功率相当,与网片相关的发病率以及对功能结局的影响相似。